Potential of CXCR1/2 as a target for the treatment of inflammation and cancer (Review)

C-X-C motif chemokine receptor (CXCR)1 and CXCR2 are chemokine receptors that serve critical roles in mediating immune and inflammatory responses. Their activation by chemokines, such as C-X-C motif chemokine ligand (CXCL)8/IL-8, can promote cell migration, proliferation and the release of additional inflammatory mediators, contributing to the progression of inflammatory diseases and cancers. By inhibiting the binding of CXCL8/IL-8 to CXCR1 and CXCR2, SCH527123 aims to disrupt these harmful processes and offers a promising therapeutic strategy. Research on immunotherapy, particularly focusing on targeting specific immune receptors and pathways, is experiencing a surge of interest and progress. Exploration of SCH527123 as a novel CXCR1 and CXCR2 antagonist has highlighted the potential of this approach in treating various diseases, particularly those involving inflammation and cancers. The preclinical success of SCH527123 in animal models of liver, pancreatic and ovarian cancers has underscored its potential as an anti-inflammatory and anti-tumor agent. These findings suggest that targeting CXCR1/2 signaling may represent a viable approach for treating a broad range of malignancies. Furthermore, interest in SCH527123 as a potential treatment for COPD and asthma has suggested its potential applications beyond cancer therapy. Therefore, SCH527123 represents a new drug candidate with potential in the fields of inflammation and cancer. Although challenges remain in translating preclinical findings into clinical benefits, ongoing research and development efforts on using SCH527123 hold promise for improving the survival and quality of life of patients with these devastating diseases.